Oxford Asset Management LLP Buys New Position in Candel Therapeutics, Inc. (NASDAQ:CADL)

Oxford Asset Management LLP bought a new stake in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,003 shares of the company’s stock, valued at approximately $104,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Russell Investments Group Ltd. raised its holdings in shares of Candel Therapeutics by 75.1% during the fourth quarter. Russell Investments Group Ltd. now owns 3,753 shares of the company’s stock valued at $33,000 after acquiring an additional 1,610 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Candel Therapeutics by 63.6% during the fourth quarter. Wells Fargo & Company MN now owns 10,122 shares of the company’s stock valued at $88,000 after acquiring an additional 3,935 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Candel Therapeutics by 15.2% during the fourth quarter. JPMorgan Chase & Co. now owns 10,426 shares of the company’s stock valued at $90,000 after acquiring an additional 1,375 shares in the last quarter. LPL Financial LLC bought a new position in shares of Candel Therapeutics during the fourth quarter valued at approximately $93,000. Finally, MetLife Investment Management LLC raised its holdings in Candel Therapeutics by 9.7% in the fourth quarter. MetLife Investment Management LLC now owns 13,773 shares of the company’s stock worth $120,000 after purchasing an additional 1,215 shares in the last quarter. Institutional investors own 13.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on CADL shares. HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of Candel Therapeutics in a report on Friday, April 11th. Canaccord Genuity Group increased their price objective on Candel Therapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, February 26th. Citigroup started coverage on Candel Therapeutics in a report on Thursday, February 20th. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Bank of America began coverage on Candel Therapeutics in a report on Friday, February 7th. They issued a “buy” rating and a $15.00 price objective for the company.

Candel Therapeutics Price Performance

Shares of NASDAQ:CADL opened at $4.97 on Tuesday. Candel Therapeutics, Inc. has a 1-year low of $3.79 and a 1-year high of $14.60. The business has a fifty day moving average price of $6.87 and a 200-day moving average price of $6.75. The company has a market capitalization of $234.76 million, a PE ratio of -2.87 and a beta of -0.95.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.17). On average, sell-side analysts anticipate that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current fiscal year.

Insider Activity at Candel Therapeutics

In related news, CTO Seshu Tyagarajan sold 31,278 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $8.82, for a total transaction of $275,871.96. Following the sale, the chief technology officer now directly owns 85,512 shares of the company’s stock, valued at $754,215.84. This trade represents a 26.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Charles Schoch sold 5,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $8.83, for a total value of $44,150.00. Following the sale, the insider now directly owns 38,038 shares in the company, valued at $335,875.54. This trade represents a 11.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 41.60% of the stock is currently owned by insiders.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.